Nearly 100 UFT members turned out at union headquarters in Manhattan on March 14 to learn the latest information on treating breast cancer from Dr. Larry Norton of Memorial Sloan Kettering. Dr. Norton, who has done similar seminars for the UFT for more than 10 years, made special note of the IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets) program, a targeted tumor-sequencing test available to MSK patients. Using the test to detect mutations and other critical changes in the genes of cancers, doctors discover whether a tumor has changes that make the cancer vulnerable to particular drugs, allowing them to match therapies and trials with the patients.